Epidiolex (Cannabidiol) in Treatment Resistant Epilepsy

Journal
Orrin Devinsky, Joseph Sullivan, Daniel Friedman, Elizabeth Thiele, Eric Marsh, Linda Laux, Ian Miller, Robert Flamini, Angus Wilfong, Francis Filloux, Matthew Wong, Nicole Tilton, Patricia Bruno, Rebecca Kamens, Jane Maclean, Judith Bluvstein, Srishti Nangia, Anup Patel, & Maria Roberta Cilio

Cannabidiol (CBD) is the most abundant nonpsychoactive cannabinoid in cannabis. Animal studies demonstrate anticonvulsant efficacy in multiple species and models. Anecdotal reports suggest CBD to be
effective in children with treatment-resistant epilepsies (TRE), especially Dravet syndrome (DS). We report results of an open label study in children with TRE in an expanded access treatment program conducted in the US under INDs. Efficacy results are reported for all patients who received at least 12 weeks of treatment (n=137). Safety
results are reported for all patients who received any
treatment (n=213)

Open Full Article

This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.

Search the Research Library

  • Conditions

  • Research Keywords

  • Search Text

  • Reset